Description
Supported by expertise in medicinal chemistry and machine learning combined with the Schrödinger suite of software, a computational platform used to accelerate drug discovery, Cayman's computer-aided drug design (CADD) program can perform homology modeling even if no target structure is available. Our multidisciplinary approach provides in silico docking analysis and identification of protein binding sites, as well as key protein-, drug-, and ligand-protein interactions, identifies hits, and guides lead optimization.